Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Otilimab IV in Severe Pulmonary COVID-19
2020-001759-42Phase 2Unknown
- Sponsor
- GSK
- Start
- May 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Otilimab IV with Placebo IV (2 arms). Primary endpoint: Participants alive and free of respiratory failure. Status: unknown.
02
Drugs
otilimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-001759-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001759-42.